Yoshimasa Kyokawa | Investor Relations |
John Keller | Senior Executive Officer and Senior Vice President, R&D Supervisory Unit |
Toshinobu Iwasaki | Senior Executive Officer, Senior Vice President, Healthcare Business Supervisory Unit and Pharmaceutical Commercial Division |
Ryuichi Kiyama | Senior Executive Officer and Senior Vice President, Corporate Strategy Division and Corporate Planning Department |
Takeki Uehara | Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division |
Susumu Mitsumori | Vice President, Finance and Accounting Department |
Hidemaru Yamaguchi | Citi |
Eiji Ueda | Goldman Sachs |
Motoya Kohtani | Nomura Securities |
Kazuaki Hashiguchi | Daiwa Securities |
Fumiyoshi Sakai | Credit Suisse |
Seiji Wakao | JPMorgan |
Naomi Kumagai | Mitsubishi UFJ Morgan Stanley |
Good afternoon. Kyokawa from the Public Relations of Shionogi Pharmaceuticals. Thank you very much for joining us today. From now, we would like to begin the presentation of the Final Results of the First Quarter of Fiscal 2022 of Shionogi & Company Limited.
First, let me introduce the people on the stage.